🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07353775
Recruiting Observational

Intracardiac Echocardiography-Guided Cavotricuspid Isthmus Ablation With a Circular-Shaped Pulsed Field Ablation Catheter

NCT07353775 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2025-01-15
Last updated
2026-01-20

Condition(s) studied

Atrial Fibrillation (AF)Atrial Flutter

Investigational drug(s) / intervention(s)

ICE-guided CTI ablation with PFA

ICE-guided CTI ablation with PFA: Cavotricuspid isthmus ablation with a circular-shaped pulsed field ablation catheter guided by intracardiac echocardiography

Study summary

This observational study aims to evaluate the effectiveness and safety of a circular-shaped pulsed field ablation (PFA) catheter for CTI ablation under the guidance of intracardiac echocardiography (ICE). The main question it aims to answer is:

Is the circular-shaped PFA catheter an effective and safe tool for achieving acute success for CTI ablation? Patients undergoing CTI ablation with a circular-shaped PFA catheter will be prospectively enrolled.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Paroxysmal or persistent atrial fibrillation * Aged 18 years or older * Scheduled for CTI ablation * Able and willing to provide written informed consent Exclusion Criteria: * Previous CTI ablation * Significant congenital heart disease or structural anomaly affecting the CTI * Active intracardiac thrombus * Pregnancy or lactation * Severe renal/hepatic insufficiency * Active systemic infection or sepsis * Life expectancy of less than 12 months * Unable to provide written informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing China Recruiting

More Beijing Anzhen Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07353775 on ClinicalTrials.gov ↗ ← All trials in China